Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Daniel Tandel Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2760-1554; OpenAlex author ID A5084612623. Sources: ClinicalTrials.gov.

Their work

Papers
46 (first author 4, last author 16)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
157
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 3 papers, 1 trial · 2014: 5 papers · 2015: 1 paper · 2016: 4 papers · 2017: 4 papers · 2018: 4 papers · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 46

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Last author DOI 10.1016/j.prro.2026.07.002↗
  2. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Co-author DOI 10.1097/sla.0000000000006609↗
  3. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  4. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  5. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  6. Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Last author DOI 10.1245/s10434-023-13120-3↗
  7. ASO Author Reflections: Reducing Subjectivity on Assessment of Pancreatic Cancer Resectability. First author DOI 10.1245/s10434-023-13295-9↗
  8. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  9. The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0069↗
  10. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institu… Co-author DOI 10.1097/mpa.0000000000001822↗
  11. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  12. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  13. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  14. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  15. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.prro.2020.02.010↗
  16. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Last author DOI 10.1016/j.radonc.2020.07.053↗
  17. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  18. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  19. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Last author DOI 10.1097/mpa.0000000000001314↗
  20. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  21. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  22. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated Wit… Co-author DOI 10.1016/j.ijrobp.2017.10.001↗
  23. Management of Borderline Resectable Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2017.12.287↗
  24. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Last author DOI 10.1097/coc.0000000000000263↗
  25. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Last author DOI 10.1016/j.adro.2017.01.003↗
  26. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.09.007↗
  27. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Last author DOI 10.1016/j.prro.2016.09.002↗
  28. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  29. Quantitative Analysis of (18)F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Ca… Co-author DOI 10.1016/j.ijrobp.2016.04.034↗
  30. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  31. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000470↗
  32. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. Co-author DOI 10.1371/journal.pone.0147995↗
  33. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… First author DOI 10.1002/cncr.29161↗
  34. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving… Co-author DOI 10.1016/j.ijrobp.2014.02.031↗
  35. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Last author DOI 10.1016/j.ijrobp.2014.06.066↗
  36. Stereotactic body radiotherapy in the treatment of pancreatic cancer. Last author DOI 10.1016/j.semradonc.2013.11.008↗
  37. Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000098↗
  38. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Co-author DOI 10.1586/14737140.2014.952286↗
  39. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Last author DOI 10.1016/j.ijrobp.2012.07.2366↗
  40. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarci… First author DOI 10.1016/j.prro.2013.01.016↗
  41. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality ther… Co-author DOI 10.3978/j.issn.2078-6891.2013.044↗
  42. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. First author DOI 10.1002/cncr.26365↗
  43. Modern radiation therapy techniques for pancreatic cancer. Last author DOI 10.1016/j.gtc.2011.12.011↗
  44. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Last author DOI 10.1016/j.ijrobp.2011.09.035↗
  45. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.05.006↗
  46. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Co-author DOI 10.1097/pas.0b013e318206c37a↗

Trials 1

  1. Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Principal investigator NCT01926197↗

Closest collaborators

The 25 strongest of 157 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Albert C. Koong · 36 shared papers, 2011–2023 · strength 2.37
  2. Diego A.S. Toesca · 10 shared papers, 2017–2026 · strength 1.47
  3. Erqi Liu Pollom · 10 shared papers, 2014–2026 · strength 1.09
  4. George A. Poultsides · 10 shared papers, 2012–2026 · strength 1.01
  5. George Albert Fisher · 10 shared papers, 2011–2026 · strength 0.88
  6. Margaret M. Kozak · 10 shared papers, 2016–2023 · strength 0.74
  7. Brendan Christopher Visser · 7 shared papers, 2012–2026 · strength 0.71
  8. Richard Francis Dunne · 9 shared papers, 2017–2023 · strength 0.69
  9. Aram F. Hezel · 9 shared papers, 2017–2023 · strength 0.69
  10. Brian Matthew Wolpin · 9 shared papers, 2017–2023 · strength 0.69
  11. Jonathan Andrew Nowak · 9 shared papers, 2017–2023 · strength 0.69
  12. Karyn A. Goodman · 7 shared papers, 2011–2026 · strength 0.65
  13. Joseph M. Herman · 10 shared papers, 2013–2023 · strength 0.60
  14. Chen Yuan · 7 shared papers, 2017–2023 · strength 0.55
  15. Thomas E. Clancy · 7 shared papers, 2017–2023 · strength 0.55
  16. Douglas Adam Rubinson · 7 shared papers, 2017–2023 · strength 0.55
  17. Vicente Morales‐Oyarvide · 7 shared papers, 2017–2023 · strength 0.55
  18. Andressa Dias Costa · 6 shared papers, 2019–2023 · strength 0.53
  19. Andrew J. Aguirre · 6 shared papers, 2018–2023 · strength 0.50
  20. David C. Linehan · 7 shared papers, 2011–2023 · strength 0.50
  21. Charles S. Fuchs · 7 shared papers, 2017–2021 · strength 0.47
  22. Amol Kumar Narang · 3 shared papers, 2018–2026 · strength 0.47
  23. Sara A. Väyrynen · 5 shared papers, 2019–2023 · strength 0.45
  24. Amanda Jeanette Koong · 4 shared papers, 2017–2021 · strength 0.42
  25. Jeffrey Allen Norton · 6 shared papers, 2011–2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.